Tradestie Institutional Equity Comparison Engine
ANNX vs CCCC โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ANNX Overall Edge
ANNX Captures Institutional Edge (3โ0 Pillars ยท 5โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Annexon, Inc. Common Stock (ANNX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, ANNX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus CCCC at N/M Forward P/E and -315.9% operating margin (-24.6% YoY). In options structure, ANNX sits in BREAKDOWN (100th %ile IV; Dealer Gamma Walls on Pro) against CCCC sits in BREAKDOWN (3rd %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
ANNX N/M vs CCCC N/M Fwd P/E
Growth & Margin Winner
ANNX
Op Margin 0.0% vs -315.9% ยท YoY +0.0% vs -24.6%
Momentum & Technical Winner
ANNX
1Y +28.6% vs +1.4% ยท 52W Pos 18% vs 23%
Options & Structure Winner
ANNX
BREAKDOWN (100th %ile IV) vs BREAKDOWN (3rd %ile IV)
ANNX
NASDAQ
Annexon, Inc. Common Stock
Pharmaceutical Preparations
$3.48
-2.38% 1D
Market Cap
$747.8M
1M Return
-13.09%
1Y Return
+28.6%
Forward P/E
N/M
Unified AI Score
43.5 / 100
HOLD
Tech 37.0
Fund 55.0
Flow 72.0
Mom 60.0
CCCC
NASDAQ
C4 Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$2.50
-5.47% 1D
Market Cap
$362.4M
1M Return
-13.32%
1Y Return
+1.42%
Forward P/E
N/M
Unified AI Score
47.7 / 100
HOLD
Tech 33.0
Fund 51.0
Flow 64.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ANNX +28.6%
CCCC +1.42%
Spread: +27.18 pp (ANNX Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
ANNX TTM Op. Margin: 0.0%
CCCC TTM Op. Margin: -315.9%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ANNX vs CCCC. Trailing 12-month operating profitability (ANNX 0.0% vs CCCC -315.9%) and valuation multiples (ANNX N/M vs CCCC N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ANNX | CCCC | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $747.8M | $362.4M | Larger Scale | ANNX |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | -24.6% | Higher Growth | ANNX |
| Operating Margin (TTM) Profitability | 0.0% | -315.9% | Higher Margin | ANNX |
| Net Profit Margin Profitability | 0.0% | -282.2% | Higher Margin | ANNX |
| Return on Equity (ROE) Capital Efficiency | -130.8% | -47.6% | Higher ROE | CCCC |
| 52-Week Range Position Momentum | 18% ($3โ$7) | 23% ($2โ$5) | Stronger Trend | CCCC |
| Beta / 30D Volatility Risk Regime | 1.69ฮฒ ยท 63% Vol | 1.46ฮฒ ยท 68% Vol | Lower Realized Risk | ANNX |
| Unified Institutional Score Composite Signal | 43.5 / 100 (HOLD) | 47.7 / 100 (HOLD) | Higher Composite | CCCC |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ANNX vs CCCC Buy Guide
ANNX
BREAKDOWN
88d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
100th %ile
IV Regime
Extreme (>80th %ile)
CCCC
BREAKDOWN
118d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
3rd %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ANNX nor CCCC registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.